Decoding Cancer's Resistance: A New Blueprint for Lung Cancer Therapy

LOS ANGELES, CA – July 21, 2026 – In a significant move to outmaneuver one of the deadliest forms of cancer, City of Hope has launched a landmark national clinical trial aimed at creating a dynamic map of how lung cancer evolves to resist treatment. Backed by up to $23.7 million from the Advanced Research Projects Agency for Health (ARPA-H), the ambitious six-year study, named IMMUNO-BIOMAP, seeks to rewrite the rulebook for treating advanced non-small cell lung cancer (NSCLC), a disease that accounts for the vast majority of lung cancer cases.

The research represents a pivotal shift from static treatment protocols to an adaptive, personalized strategy. By tracking tumor changes in real time, investigators aim to predict which patients will benefit from immunotherapy and, crucially, determine the best next step when a treatment begins to fail. It’s a project that sits at the intersection of cutting-edge genomics, data science, and patient care, addressing one of the most persistent challenges in modern oncology.

The Immunotherapy Paradox

For the past decade, immunotherapy has been hailed as a revolutionary pillar of cancer treatment. Drugs known as immune checkpoint inhibitors, which unleash the body’s own immune system to attack cancer cells, have produced remarkable, long-lasting responses in some patients with advanced NSCLC. Yet this success story comes with a significant caveat: the revolution has not reached everyone. Fewer than 40% of patients see a positive result from these powerful drugs, and a significant portion of those who initially respond eventually watch their cancer adapt, resist, and progress.

This challenge of resistance—both primary (when the drug never works) and acquired (when it stops working)—is the central problem that the IMMUNO-BIOMAP trial is designed to solve. Current methods for predicting a patient's response, such as measuring the PD-L1 protein on cancer cells, are imperfect. They provide a single snapshot of a complex and constantly changing biological landscape, leaving doctors and patients in a reactive posture, often waiting for a tumor to grow on a scan before they can change course. This trial proposes to get ahead of the disease, turning oncology from a reactive discipline into a predictive one.

A Dynamic Blueprint for a Moving Target

The core innovation of IMMUNO-BIOMAP lies in its longitudinal approach. Rather than relying on a single biopsy, the trial will follow 535 newly diagnosed NSCLC patients over time, collecting tumor and blood samples at multiple points. The goal is to create a high-resolution “movie” of the tumor’s evolution, not just a single photograph.

Central to this strategy is the use of circulating tumor DNA (ctDNA), often called a “liquid biopsy.” As tumor cells die, they release fragments of their DNA into the bloodstream. By analyzing this DNA from a simple blood draw, researchers can monitor the tumor's genetic makeup in real time, detecting the emergence of mutations that confer resistance long before they would be visible on a CT scan.

“Our goal is to create clear guidelines for selecting the best next treatment when a patient's cancer doesn't respond to initial therapy,” said lead principal investigator Dr. Ravi Salgia, a professor and chair at City of Hope. “City of Hope is determined to find a reliable way to predict who will benefit from immunotherapy and who might experience better results with other treatment options.”

The trial will dive deep into the world of biomarkers—the biological clues that can help match a patient’s specific cancer to the most effective therapy. By understanding the intricate dance between the immune system and the tumor, the team hopes to solve a key puzzle in lung cancer treatment.

“Late-stage non-small cell lung cancer is unique in that a patient’s response to initial therapy often influences the success of later treatment,” explained principal investigator Dr. Aritro Nath, an assistant professor at the institution. “Unraveling this mystery is one of our key objectives.”

This real-time monitoring capability is what makes the trial’s second phase so promising. Researchers will use the biomarker data they gather to guide therapies in real time, aiming to halt disease progression by staying one step ahead of the cancer’s adaptive strategies. It’s a dynamic approach for a dynamic disease.

“Measuring tumor DNA levels in the blood over time will help us pinpoint which patients face a greater risk for drug resistance and relapse after immunotherapy,” said Dr. Jyoti Malhotra, a principal investigator and director of Thoracic Medical Oncology at City of Hope Orange County. “Understanding how checkpoint drugs interact with tumor cells will allow us to tailor treatment plans based on each patient’s unique cancer DNA signature, enhancing the likelihood of a successful outcome.”

A Strategic Bet on High-Impact Science

The substantial funding for this trial comes from ARPA-H, a federal agency established to accelerate high-impact biomedical and health breakthroughs. Modeled after the Defense Advanced Research Projects Agency (DARPA), which is credited with developing technologies like the internet and GPS, ARPA-H is designed to support high-risk, high-reward projects that traditional funding mechanisms might overlook. Its purpose is to deliver tangible health solutions on an accelerated timeline.

IMMUNO-BIOMAP is funded through ARPA-H’s Advanced Analysis for Precision Cancer Therapy (ADAPT) program, a $142 million initiative aiming to build a network of technologies and experts to make cancer care more precise and adaptive. City of Hope’s selection as the only institution to receive ADAPT funding for lung cancer research underscores its leadership in the field and the national significance of this work. This isn't just another trial; it's a strategic component of a national effort to revolutionize how cancer is managed.

From the Lab to the Lives of Patients

For the more than 200,000 people diagnosed with lung cancer in the United States each year, the implications of this research are profound. Success in this trial could mean a future where treatment is no longer a matter of trial and error but a precise, data-driven decision from the start. It offers the possibility of avoiding the physical and emotional toll of ineffective therapies and extending lives by keeping the disease under control for longer.

To ensure its findings are applicable to the diverse population affected by lung cancer, the trial will draw on City of Hope’s extensive national system, which includes nearly 40 clinical sites across the country. This broad reach is critical for both enrolling a representative patient cohort and, eventually, deploying the validated predictive models into clinical practice nationwide.

By building a system that learns from each patient, the IMMUNO-BIOMAP trial aims to create a feedback loop where every individual’s treatment journey contributes to a deeper understanding of the disease, benefiting countless future patients.

“We believe that the insights gained from this trial will transform how doctors manage care for non-small cell lung cancer patients,” Dr. Salgia concluded. “Our findings offer hope for greater treatment success and longer lives.”